Tools
Upgrade to Pro 🌟

Upgrade for Pro stock ideas, Al signals, and more search.

Learn More

PBE

Invesco Biotechnology & Genome ETF · PSE

  • Category Health Care
  • Expense Ratio 0.58%
  • Listing Date Jun 23, 2005
  • Volume 36,196.0
  • Market Cap (AUM) $252.98M

Performance

-4.72%

1W

-2.36%

1M

-5.35%

3M

+4.72%

6M

+2.79%

YTD

+19.03%

1Y

Top Holdings

  • Name
    Symbol
    %Assets
  • BioMarin Pharmaceutical Inc.BMRN5.59%
  • Incyte CorporationINCY5.35%
  • Regeneron Pharmaceuticals, Inc.REGN5.27%
  • Gilead Sciences, Inc.GILD5.26%
  • Vertex Pharmaceuticals IncorporatedVRTX5.18%
  • Amgen Inc.AMGN5.07%
  • Illumina, Inc.ILMN5.06%
  • Neurocrine Biosciences, Inc.NBIX4.69%
  • Halozyme Therapeutics, Inc.HALO3.16%
  • Intra-Cellular Therapies, Inc.ITCI3.09%

Technical Analysis of PBE 2024-11-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 23 indicating strong bearish momentum, while the Technical Score of 36 further supports this outlook. The Oscillators Score of 50 suggests a neutral position, but it does not outweigh the prevailing bearish signals from the other indicators.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.